Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000236434

Medchemexpress LLC 3,4-dichloro-1-(2,4-dimethoxybenzyl)-1H-pyrrole-2,5-dione | 342416-30-2 | 98.0% | 316.14 g·mol⁻1 | C13H11Cl2NO4 | 5MG
SDP

Catalog No. 5000236434
Encompass_Preferred

IRES-C11 is a small-molecule inhibitor that selectively blocks c-MYC internal ribosome entry site (IRES)-mediated translation by preventing heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) binding. It reduces c-MYC and cyclin D1 IRES activity in vitro (significant effects observed at ~50 nM) and has shown synergistic anti-glioblastoma effects when combined with mTOR inhibitors. The compound is supplied as a solid powder and as a 10 mM solution in DMSO for research use.

  • Selective inhibitor of c-MYC IRES-mediated translation.
  • Blocks hnRNP A1 interaction with the c-MYC IRES.
  • Reduces c-MYC and cyclin D1 protein levels at nanomolar concentrations.
  • Demonstrates synergy with mTOR inhibitors in glioblastoma models.
  • Available as powder and as a 10 mM solution in DMSO for in vitro studies.
  • High purity (98.01%) and molecular weight 316.14 g·mol⁻1.

Catalog No. 50-002-36434 Supplier Medchemexpress LLC Supplier No. HY1248115MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

IRES-C11 is a small-molecule inhibitor that selectively blocks c-MYC internal ribosome entry site (IRES)-mediated translation by preventing heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) binding. It reduces c-MYC and cyclin D1 IRES activity in vitro (significant effects observed at ~50 nM) and has shown synergistic anti-glioblastoma effects when combined with mTOR inhibitors. The compound is supplied as a solid powder and as a 10 mM solution in DMSO for research use.

  • Selective inhibitor of c-MYC IRES-mediated translation.
  • Blocks hnRNP A1 interaction with the c-MYC IRES.
  • Reduces c-MYC and cyclin D1 protein levels at nanomolar concentrations.
  • Demonstrates synergy with mTOR inhibitors in glioblastoma models.
  • Available as powder and as a 10 mM solution in DMSO for in vitro studies.
  • High purity (98.01%) and molecular weight 316.14 g·mol⁻1.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.